Premium
Characterization of a novel metastatic prostate cancer cell line of LNCaP origin
Author(s) -
Castanares Mark A.,
Copeland Ben T.,
Chowdhury Wasim H.,
Liu Minzhi M.,
Rodriguez Ronald,
Pomper Martin G.,
Lupold Shawn E.,
Foss Catherine A.
Publication year - 2016
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.23115
Subject(s) - lncap , prostate cancer , cancer research , medicine , lymph node , prostate , androgen , metastasis , androgen receptor , cancer , oncology , hormone
BACKGROUND The LNCaP cell line was originally isolated from the lymph node of a patient with metastatic prostate cancer. Many cell lines have been derived from LNCaP by selective pressures to study different aspects of prostate cancer progression. When injected subcutaneously into male athymic nude mice, LNCaP and its derivatives rarely metastasize. METHODS Here, we describe the characteristics of a new LNCaP derivative, JHU‐LNCaP‐SM, which was generated by long term passage in normal cell culture conditions. RESULTS Short tandem repeat (STR) analysis and genomic sequencing verified JHU‐LNCaP‐SM derivation from parental LNCaP cells. JHU‐LNCaP‐SM cells express the same mutated androgen receptor (AR) but unlike LNCaP, are no longer androgen dependent for growth. The cells demonstrate an attenuated androgen responsiveness in transcriptional assays and retain androgen sensitive expression of PSA, AR, and PSMA. Unlike parental LNCaP, JHU‐LNCaP‐SM cells quickly form subcutaneous tumors in male athymic nude mice, reliably metastasize to the lymph nodes and display a striking intra‐tumoral and spreading hemorrhagic phenotype as tumor xenografts. CONCLUSIONS The JHU‐LNCaP‐SM cell line is a new isolate of LNCaP, which facilitates practical, preclinical studies of spontaneous metastasis of prostate cancer through lymphatic tissues. Prostate 76:215–225, 2016 . © 2015 Wiley Periodicals, Inc.